secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0001558370-23-003572
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales
--------------------------------------------------------------------------------

- Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.
- Received $200M milestone from Rayner in Feb 2023; OMIDRIA Q4 royalties $17.9M on record $35.8M sales.
- Cash and short-term investments $194.9M; accounts receivable $213M now collected; no SVB exposure.
- Preparing narsoplimab BLA resubmission for TA-TMA; FDA meeting expected Q2 2023; ARTEMIS-IGAN data Q3 2023.
- Initiated OMS906 trials in PNH (treatment-naïve and ravulizumab inadequate response) and C3G; OMS1029 quarterly dosing possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/0001558370-23-003572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/omer-20230313x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer